Understanding your tumor biology is key to finding the right treatment for pancreatic cancer. Identifying mutations, or changes in a [...] READ MORE ...

A new study by Mayo Clinic Comprehensive Cancer Center researchers found that the presence of a specific genetic ...

PDAC, an aggressive and often difficult-to-diagnose cancer, frequently spreads before detection. The study, published in the ...

Explore the medical isotopes market growth, trends, innovations, and applications in healthcare, diagnostics, and therapy. Discover key drivers, challenges, and opportunities shaping the industry.

Encouraging preclinical data supporting the use of DNase-based technology to target NETosis and address difficult to treat cancers ...

The study demonstrates that PAC-MANN-1 outperforms the widely used CA 19-9 biomarker, offering greater accuracy in detecting all stages of PDAC. The assay is particularly promising for identifying ...

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related mortality worldwide. Current treatment modalities are few or ...

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit writes about the critical federal funding at risk and what this ...

The trial’s first phase will begin in university hospitals across the Netherlands, Denmark, Germany and Sweden.

The FDA has granted orphan drug designation to PEP-010 for pancreatic cancer, advancing its development as a potential novel ...

In recent study, PAC-MANN identified pancreatic ductal adenocarcinoma samples with 98 percent specificity and 73 percent sensitivity across all stages.